NCT02839668 - The Impact of Intravenous Anaesthesia on Angiogenesis in Patients With Breast Cancer (TIVA/TCI-BC) | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions

Breast Cancer

Interventions

DRUG

Lidocaine

Continuous infusion of lidocaine

DRUG

Sevoflurane

maintenance of hypnosis during anaesthesia with sevoflurane

DRUG

TIVA-TCI

maintenance of hypnosis during anaesthesia with sevoflurane

DRUG

Acetaminophen

administration of 1 g acetaminophen for postoperative analgesia

DRUG

Tramadol

administration of tramadol for postoperative analgesia

DRUG

Neostigmine

A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.

DRUG

Atropine

A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine

DEVICE

BIS

For the groups receveing TIVA-TCI anesthesia the bispectral index will be monitored

Trial Locations (1)

IOCN Prof Dr I chiricuta, Cluj-Napoca

All Listed Sponsors

collaborator

Prof. Dr. I. Chiricuta Institute of Oncology

OTHER

lead

Iuliu Hatieganu University of Medicine and Pharmacy

OTHER